AIM: To investigate the effects of autologous tumor vaccine on recurrence of hepatocellular carcinoma (HCC). METHODS:Sixty patients with HCC who had undergone curative resection, were randomly divided into HCC vaccine group and control group. Three vaccinations at 2-wk intervals were performed after curative hepatic resection. Delayed-type- hypersensitivity (DTH) test was performed before and after vaccination. Primary endpoints were the time of recurrence. RESULTS: Four patients in control group and 6 patients in HCC vaccine group were withdrawn from the study. The vaccine containing human autologous HCC fragments showed no essential adverse effect in a phase II clinical trial and 17 of 24 patients developed a DTH response against the fragments. Three of 17 DTH-positive response patients and 5 of 7 DTH-negative response patients had recurrences after curative resection. After the operation, 1-, 2- and 3-year recurrence rates of HCC vaccine group were 16.7%, 29.2% and 33.3%, respectively. But, 1-, 2- and 3-year recurrence rates of the control group were 30.8%, 53.8% and 61.5%, respectively. The time before the first recurrence in the vaccinated patients was significantly longer than that in the control patients (P < 0.05). CONCLUSION:Autologous tumor vaccine is of promise in decreasing recurrence of human HCC.
RCT Entities:
AIM: To investigate the effects of autologous tumor vaccine on recurrence of hepatocellular carcinoma (HCC). METHODS: Sixty patients with HCC who had undergone curative resection, were randomly divided into HCC vaccine group and control group. Three vaccinations at 2-wk intervals were performed after curative hepatic resection. Delayed-type- hypersensitivity (DTH) test was performed before and after vaccination. Primary endpoints were the time of recurrence. RESULTS: Four patients in control group and 6 patients in HCC vaccine group were withdrawn from the study. The vaccine containing human autologous HCC fragments showed no essential adverse effect in a phase II clinical trial and 17 of 24 patients developed a DTH response against the fragments. Three of 17 DTH-positive response patients and 5 of 7 DTH-negative response patients had recurrences after curative resection. After the operation, 1-, 2- and 3-year recurrence rates of HCC vaccine group were 16.7%, 29.2% and 33.3%, respectively. But, 1-, 2- and 3-year recurrence rates of the control group were 30.8%, 53.8% and 61.5%, respectively. The time before the first recurrence in the vaccinated patients was significantly longer than that in the control patients (P < 0.05). CONCLUSION: Autologous tumor vaccine is of promise in decreasing recurrence of human HCC.
Authors: W S Meng; L H Butterfield; A Ribas; V B Dissette; J B Heller; G A Miranda; J A Glaspy; W H McBride; J S Economou Journal: Cancer Res Date: 2001-12-15 Impact factor: 12.701
Authors: C M Vollmer; F C Eilber; L H Butterfield; A Ribas; V B Dissette; A Koh; L D Montejo; M C Lee; K J Andrews; W H McBride; J A Glaspy; J S Economou Journal: Cancer Res Date: 1999-07-01 Impact factor: 12.701
Authors: F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts Journal: Hepatology Date: 2001-06 Impact factor: 17.425
Authors: R Soiffer; T Lynch; M Mihm; K Jung; C Rhuda; J C Schmollinger; F S Hodi; L Liebster; P Lam; S Mentzer; S Singer; K K Tanabe; A B Cosimi; R Duda; A Sober; A Bhan; J Daley; D Neuberg; G Parry; J Rokovich; L Richards; J Drayer; A Berns; S Clift; L K Cohen; R C Mulligan; G Dranoff Journal: Proc Natl Acad Sci U S A Date: 1998-10-27 Impact factor: 11.205
Authors: John M Kirkwood; Lisa H Butterfield; Ahmad A Tarhini; Hassane Zarour; Pawel Kalinski; Soldano Ferrone Journal: CA Cancer J Clin Date: 2012-05-10 Impact factor: 508.702
Authors: K Sideras; S J Bots; K Biermann; D Sprengers; W G Polak; J N M IJzermans; R A de Man; Q Pan; S Sleijfer; M J Bruno; J Kwekkeboom Journal: Br J Cancer Date: 2015-06-09 Impact factor: 7.640
Authors: Clifford Akateh; Sylvester M Black; Lanla Conteh; Eric D Miller; Anne Noonan; Eric Elliott; Timothy M Pawlik; Allan Tsung; Jordan M Cloyd Journal: World J Gastroenterol Date: 2019-07-28 Impact factor: 5.742
Authors: Kota Sahara; S Ayesha Farooq; Diamantis I Tsilimigras; Katiuscha Merath; Anghela Z Paredes; Lu Wu; Rittal Mehta; J Madison Hyer; Itaru Endo; Timothy M Pawlik Journal: Hepatobiliary Surg Nutr Date: 2020-02 Impact factor: 7.293